Anthrax / protease

Inhibition of anthrax lethal factor protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to inhibitors of anthrax lethal factor protease activity. 2. Description of the Related Art Anthrax, a disease caused by Bacillus anthracis, has recently been the subject of intense interest because of its

Anthrax lethal factor is a MAPK kinase protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to tranformed

Anthrax lethal factor is a MAPK kinase protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not applicable. FIELD OF THE INVENTION The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as

Anthrax lethal factor is a MAPK kinase protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not applicable. FIELD OF THE INVENTION The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as

Anthrax lethal factor is a MAPK kinase protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not applicable. FIELD OF THE INVENTION The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as

Anthrax lethal factor is a mapk kinase protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not applicable. FIELD OF THE INVENTION The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as

Peptide biosensors for anthrax protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention is in the field of fluorescence-based cell and molecular biochemical assays for toxin detection and drug discovery. BACKGROUND OF THE INVENTION Bacillus anthracis is the causative agent of anthrax, which is characterized by the hyperstimulation of host

Engineered anthrax protective antigen proteins for cancer therapy

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

SEQUENCE LISTING A sequence listing in electronic (ASCII text file) format is filed with this application and incorporated herein by reference. The name of the ASCII text file is "2016_ 0823A_ST25.txt"; the file was created on Aug. 18, 2016; the size of the file is 74 KB. BACKGROUND Proteolytic

Inhibitors of lethal factor protease

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION The development of new biodefense therapeutics against anthrax and botulinum neurotoxins (BoNT) has heightened with the recent threat of these agents being used as biological weapons. Lethal factor (LF), a component of the anthrax tripartite exotoxin, cleaves

Anthrax toxin fusion proteins and related methods

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION The targeting of cytotoxic or other moieties to specific cell types has been proposed as a method of treating diseases such as cancer. Various toxins including Diphtheria toxin and Pseudomonas exotoxin A have been suggested as potential candidate toxins for this type of

Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to compositions and methods for inhibition of bacterial infections comprising Gram negative, Gram positive, and acid fast bacilli in general and mycobacterium tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular, as well

Bacillus anthracis protective antigen nucleic acid sequences

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. BACKGROUND Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a

Methods of using Bacillus anthracis protective antigen sequences for vaccination

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. BACKGROUND Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a

Methods for preparing Bacillus anthracis protective antigen for use in vaccines

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. BACKGROUND Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a

Recombinant modified Bacillus anthracis protective antigen for use in vaccines

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to improved methods for preparing Bacillus anthracis mutants and for producing recombinant Bacillus anthracis protective antigen (PA) for use in vaccines. BACKGROUND OF THE INVENTION Anthrax, a potentially fatal disease, is caused by Bacillus anthracis.

anthrax/protease

Inhibition of anthrax lethal factor protease

Anthrax lethal factor is a MAPK kinase protease

Anthrax lethal factor is a MAPK kinase protease

Anthrax lethal factor is a MAPK kinase protease

Anthrax lethal factor is a MAPK kinase protease

Anthrax lethal factor is a mapk kinase protease

Peptide biosensors for anthrax protease

Engineered anthrax protective antigen proteins for cancer therapy

Inhibitors of lethal factor protease

Anthrax toxin fusion proteins and related methods

Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections

Bacillus anthracis protective antigen nucleic acid sequences

Methods of using Bacillus anthracis protective antigen sequences for vaccination

Methods for preparing Bacillus anthracis protective antigen for use in vaccines

Recombinant modified Bacillus anthracis protective antigen for use in vaccines

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen